Great Basin Sci (GBSN) 3.73 $GBSN CORRECTING an
Post# of 273242
Posted On: 09/19/2016 7:01:39 PM
Great Basin Sci (GBSN) 3.73 $GBSN
CORRECTING and REPLACING Great Basin Announces Effectiveness of Reverse Stock Split of Common Stock
BusinessWire - Fri Sep 16, 10:53AM CDT
First paragraph, second sentence of release should read: The Company's common stock will begin trading at the open of today's market on a split-adjusted basis under new CUSIP number 39013L601 (instead of ... new CUSIP number 39013L502).
GBSN: 3.73 (-0.22)
Great Basin Announces Effectiveness of Reverse Stock Split of Common Stock
BusinessWire - Fri Sep 16, 7:30AM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that it has effected a 1-for-80 reverse split of its common stock, par value $0.0001. The Company's common stock will begin trading at the open of today's market on a split-adjusted basis under new CUSIP number 39013L502. The reverse split reduced the number of shares outstanding from 78.4 million to approximately 1.0 million.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Announces Reverse Stock Split of Common Stock
BusinessWire - Wed Sep 14, 4:30PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that a 1-for-80 reverse split of its common stock will be effective at 12:01 am EDT on September 16, 2016. The Company's common stock will open for trading on the Nasdaq Capital Market on September 16, 2016 on a post-split basis. At the effective time of the reverse stock split, every 80 shares of the Company's issued and outstanding common stock, par value $0.0001, will be consolidated into one newly-issued and outstanding share of common stock, par value of $0.0001.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Scientific Announces Annual Meeting Results
BusinessWire - Mon Sep 12, 3:25PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today approval of all but one proposal during the 2016 Annual Meeting of Stockholders. Shareholders elected two members to the Board of Directors and approved the Series E Warrants Exchange, the Nasdaq 20% Issuance, and the Adjournment proposals. Shareholders also approved a reverse stock split and ratified the appointment of the Company's independent registered public accounting firm. Shareholders did not approve an increase in the number of authorized shares from 200 million to 350 million.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Healthcare Stocks Under Review -- Exact Sciences, Great Basin Scientific, Agilent Technologies, and Thermo Fisher Scientific
PR Newswire - Thu Sep 08, 6:30AM CDT
The Medical Laboratories market continues to grow at a fast pace due to scientific advances and aging population. This segment includes bacteriological, histological, pathological and chemical analysis, urinalysis, and dental and medical X-rays. Stocks under assessment on Stock-Callers.com today are: Exact Sciences Corp. (NASDAQ: EXAS), Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), and Thermo Fisher Scientific Inc. (NYSE: TMO). Learn more about these stocks by downloading their free research reports in PDF format at:
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28), TMO: 150.00 (-0.05), A: 44.95 (+0.16), EXAS: 20.31 (+0.91)
Great Basin Scientific Receives Delisting Warning from Nasdaq
BusinessWire - Tue Sep 06, 3:55PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that it received a delisting warning from Nasdaq after 30 consecutive days of its common stock trading below the $1 minimum bid price, making it non-compliant with Nasdaq Listing Rule 5550(a)(2). The Company will have until February 27, 2017 to regain compliance by maintaining a minimum bid price of $1 for a minimum 10 consecutive days at any time within the next 180 days.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Reports Second Quarter 2016 Results
BusinessWire - Thu Aug 11, 3:02PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostic testing company, today reported financial results for the second quarter ended June 30, 2016.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Announces Commercial Launch of Shiga Toxin Direct Test
BusinessWire - Tue Aug 02, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today the commercial launch of its Shiga Toxin Direct Test, the only stand-alone test to provide the Center for Disease Control's (CDC) recommended identification of the high-virulence serotype O157 in conjunction with detecting Shiga toxin-producing Escherichia Coli, or STEC, giving clinicians definitive patient diagnosis to make timely decisions on the right course of treatment. The Company reports it began evaluations at sites in July and reaffirms that it expects to attain 50 percent penetration of its installed customer base using the Shiga Toxin Direct Test within five to seven months.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Premarket Research Report Covering the Medical Laboratories & Research Industry
ACCESSWIRE - Thu Jun 09, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 9, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Laboratories & Research industry. Companies recently under review include Thermo Fisher Scientific, Great Basin Scientific, PerkinElmer, and Organovo. Register with us now for your free membership and see our complete reports on these equities at:
GBSN: 3.73 (-0.22), TMO: 150.00 (-0.05), ONVO: 4.02 (-0.03), PKI: 53.82 (+0.50)
Great Basin Attends ASM Microbe 2016 to Transform the Way Hospitals Diagnose Infectious Disease
BusinessWire - Thu Jun 09, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today it is bringing its innovative solution to ASM Microbe 2016 in Boston, Mass., June 17-20 to help small to medium-sized hospitals learn more about the company's cost-effective, sample-to-result platform to reduce costs, increase efficiency and provide better patient outcomes. ASM Microbe 2016--integrating the American Society for Microbiology's two premier events, the General Meeting and ICAAC--showcases the best microbial sciences in the world and provides a one-of-a-kind forum to explore the complete spectrum of microbiology, from basic science to translation and application. Great Basin will be exhibiting in booth 219, where ASM attendees can receive one-on-one demonstrations of the platform and schedule meetings with Product and Sales team leaders.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Begins Clinical Trial for Stool Bacterial Pathogens Panel
BusinessWire - Tue Jun 07, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it has initiated a clinical trial for its Stool Bacterial Pathogens Panel, a multi-plex molecular assay detecting common bacterial agents, including foodborne pathogens, present in individuals suspected of acute gastroenteritis. The Stool Bacterial Pathogens Panel is the Company's second multiplex panel.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Scientific Closes $6.0 Million Public Offering of Units
BusinessWire - Wed Jun 01, 10:55AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today announced it has closed its previously announced public offering of 3.16 million units at a public offering price of $1.90 per unit. The gross proceeds from the offering of the units were approximately $6.0 million. Each unit consists of one share of common stock and one Series G warrant. Each Series G warrant will entitle the holder to acquire one share of common stock at an exercise price of $1.90 per share, subject to adjustment, for a period of five years following the date of issuance.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Co-founder and CEO, Ryan Ashton, Speaking at Marcum and LD Micro Investment Conferences
BusinessWire - Fri May 27, 12:00PM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that Co-founder and Chief Executive Officer, Ryan Ashton, will be a featured presenter at the Marcum Microcap Conference in New York on June 2, 2016 from 2:30 to 3:00 PM EDT in the Juilliard meeting room. The following week, Mr. Ashton will speak at the LD Micro Invitational in Los Angeles on June 7, 2016 from 10:30 to 11:00 AM PDT, Track 4.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Scientific Prices $6 Million Public Offering of Units
BusinessWire - Thu May 26, 8:15AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it has priced a public offering of 3.16 million units at a public offering price of $1.90 per unit. The Company expects that the gross proceeds of the offering of the units will be approximately $6 million. Each unit will consist of one share of common stock and one Series G warrant. Each Series G warrant will entitle the holder to acquire one share of common stock at an exercise price of $1.90 per share, subject to adjustment, for a period of five years following the date of issuance.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Initiates Clinical Trial For Bordatella Direct Test
BusinessWire - Tue May 17, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it has initiated a clinical trial for its sample-to-result Bordatella Direct Test, which will detect, directly from patient specimen, Bordatella pertussis, a bacterium causing a highly contagious respiratory disease commonly known as whooping cough. This is the first of five clinical trials the Company plans to initiate in 2016.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Reports First Quarter 2016 Results
BusinessWire - Thu May 12, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostic testing company, today reported financial results for the first quarter ended March 31, 2016.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Announces Rescheduling of Nasdaq Hearing
BusinessWire - Tue May 10, 3:45PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, today announced that it has received notice from Nasdaq that the date of its hearing before the Nasdaq Listing Qualifications Panel (the "Panel"
has been rescheduled by Nasdaq from mid-May to mid-June, and therefore the Company now expects a decision from the Panel in mid-July.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Expands Product Development Leadership
BusinessWire - Wed Apr 27, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, has appointed Suzette Chance, Ph.D. to serve as senior director of clinical affairs. In her role, Dr. Chance will lead clinical trial strategy and execution for Great Basin's diagnostic products, beginning with upcoming trials for: Candida Blood Infections Panel; SA Nasal Screen Test; CT/NG Test; Stool Bacterial Pathogens Panel; and Pertussis/Parapertussis Test. All five trials are slated to begin in 2016 with expected clearance timeframes throughout 2017.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Emerging Growth Mobile App Friendable, FDBL The Next Big Thing - Stocks To Watch For This Summer
ACCESSWIRE - Mon Apr 18, 7:30AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Mobile App Friendable, (OTC Pink: FDBL) The Next Big Thing. Friendable announced surpassing 700,000 registered users and a 170% increase in registered users over January and February.
NETE: 1.27 (unch), VRX: 27.10 (-0.18), GBSN: 3.73 (-0.22), SUNE: 0.34 (unch), NXTD: 3.62 (-0.09), AAPL: 113.58 (-1.34)
4 Stocks That Are Bouncing Off 52 Week Lows For Big Gains This Morning
ACCESSWIRE - Fri Apr 15, 9:16AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. GBSN, EBIO, ORPN and EXXI are on high volume alert. Continue reading to find out why GBSN could be the most talked about stock today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EXXI: 0.13 (-0.01), GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28), EBIO: 3.25 (-0.45), ORPN: 1.70 (-0.01)
CORRECTING and REPLACING Great Basin Announces Effectiveness of Reverse Stock Split of Common Stock
BusinessWire - Fri Sep 16, 10:53AM CDT
First paragraph, second sentence of release should read: The Company's common stock will begin trading at the open of today's market on a split-adjusted basis under new CUSIP number 39013L601 (instead of ... new CUSIP number 39013L502).
GBSN: 3.73 (-0.22)
Great Basin Announces Effectiveness of Reverse Stock Split of Common Stock
BusinessWire - Fri Sep 16, 7:30AM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that it has effected a 1-for-80 reverse split of its common stock, par value $0.0001. The Company's common stock will begin trading at the open of today's market on a split-adjusted basis under new CUSIP number 39013L502. The reverse split reduced the number of shares outstanding from 78.4 million to approximately 1.0 million.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Announces Reverse Stock Split of Common Stock
BusinessWire - Wed Sep 14, 4:30PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that a 1-for-80 reverse split of its common stock will be effective at 12:01 am EDT on September 16, 2016. The Company's common stock will open for trading on the Nasdaq Capital Market on September 16, 2016 on a post-split basis. At the effective time of the reverse stock split, every 80 shares of the Company's issued and outstanding common stock, par value $0.0001, will be consolidated into one newly-issued and outstanding share of common stock, par value of $0.0001.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Scientific Announces Annual Meeting Results
BusinessWire - Mon Sep 12, 3:25PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today approval of all but one proposal during the 2016 Annual Meeting of Stockholders. Shareholders elected two members to the Board of Directors and approved the Series E Warrants Exchange, the Nasdaq 20% Issuance, and the Adjournment proposals. Shareholders also approved a reverse stock split and ratified the appointment of the Company's independent registered public accounting firm. Shareholders did not approve an increase in the number of authorized shares from 200 million to 350 million.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Healthcare Stocks Under Review -- Exact Sciences, Great Basin Scientific, Agilent Technologies, and Thermo Fisher Scientific
PR Newswire - Thu Sep 08, 6:30AM CDT
The Medical Laboratories market continues to grow at a fast pace due to scientific advances and aging population. This segment includes bacteriological, histological, pathological and chemical analysis, urinalysis, and dental and medical X-rays. Stocks under assessment on Stock-Callers.com today are: Exact Sciences Corp. (NASDAQ: EXAS), Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), and Thermo Fisher Scientific Inc. (NYSE: TMO). Learn more about these stocks by downloading their free research reports in PDF format at:
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28), TMO: 150.00 (-0.05), A: 44.95 (+0.16), EXAS: 20.31 (+0.91)
Great Basin Scientific Receives Delisting Warning from Nasdaq
BusinessWire - Tue Sep 06, 3:55PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that it received a delisting warning from Nasdaq after 30 consecutive days of its common stock trading below the $1 minimum bid price, making it non-compliant with Nasdaq Listing Rule 5550(a)(2). The Company will have until February 27, 2017 to regain compliance by maintaining a minimum bid price of $1 for a minimum 10 consecutive days at any time within the next 180 days.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Reports Second Quarter 2016 Results
BusinessWire - Thu Aug 11, 3:02PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostic testing company, today reported financial results for the second quarter ended June 30, 2016.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Announces Commercial Launch of Shiga Toxin Direct Test
BusinessWire - Tue Aug 02, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today the commercial launch of its Shiga Toxin Direct Test, the only stand-alone test to provide the Center for Disease Control's (CDC) recommended identification of the high-virulence serotype O157 in conjunction with detecting Shiga toxin-producing Escherichia Coli, or STEC, giving clinicians definitive patient diagnosis to make timely decisions on the right course of treatment. The Company reports it began evaluations at sites in July and reaffirms that it expects to attain 50 percent penetration of its installed customer base using the Shiga Toxin Direct Test within five to seven months.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Premarket Research Report Covering the Medical Laboratories & Research Industry
ACCESSWIRE - Thu Jun 09, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 9, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Laboratories & Research industry. Companies recently under review include Thermo Fisher Scientific, Great Basin Scientific, PerkinElmer, and Organovo. Register with us now for your free membership and see our complete reports on these equities at:
GBSN: 3.73 (-0.22), TMO: 150.00 (-0.05), ONVO: 4.02 (-0.03), PKI: 53.82 (+0.50)
Great Basin Attends ASM Microbe 2016 to Transform the Way Hospitals Diagnose Infectious Disease
BusinessWire - Thu Jun 09, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today it is bringing its innovative solution to ASM Microbe 2016 in Boston, Mass., June 17-20 to help small to medium-sized hospitals learn more about the company's cost-effective, sample-to-result platform to reduce costs, increase efficiency and provide better patient outcomes. ASM Microbe 2016--integrating the American Society for Microbiology's two premier events, the General Meeting and ICAAC--showcases the best microbial sciences in the world and provides a one-of-a-kind forum to explore the complete spectrum of microbiology, from basic science to translation and application. Great Basin will be exhibiting in booth 219, where ASM attendees can receive one-on-one demonstrations of the platform and schedule meetings with Product and Sales team leaders.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Begins Clinical Trial for Stool Bacterial Pathogens Panel
BusinessWire - Tue Jun 07, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it has initiated a clinical trial for its Stool Bacterial Pathogens Panel, a multi-plex molecular assay detecting common bacterial agents, including foodborne pathogens, present in individuals suspected of acute gastroenteritis. The Stool Bacterial Pathogens Panel is the Company's second multiplex panel.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Scientific Closes $6.0 Million Public Offering of Units
BusinessWire - Wed Jun 01, 10:55AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today announced it has closed its previously announced public offering of 3.16 million units at a public offering price of $1.90 per unit. The gross proceeds from the offering of the units were approximately $6.0 million. Each unit consists of one share of common stock and one Series G warrant. Each Series G warrant will entitle the holder to acquire one share of common stock at an exercise price of $1.90 per share, subject to adjustment, for a period of five years following the date of issuance.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Co-founder and CEO, Ryan Ashton, Speaking at Marcum and LD Micro Investment Conferences
BusinessWire - Fri May 27, 12:00PM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that Co-founder and Chief Executive Officer, Ryan Ashton, will be a featured presenter at the Marcum Microcap Conference in New York on June 2, 2016 from 2:30 to 3:00 PM EDT in the Juilliard meeting room. The following week, Mr. Ashton will speak at the LD Micro Invitational in Los Angeles on June 7, 2016 from 10:30 to 11:00 AM PDT, Track 4.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Scientific Prices $6 Million Public Offering of Units
BusinessWire - Thu May 26, 8:15AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it has priced a public offering of 3.16 million units at a public offering price of $1.90 per unit. The Company expects that the gross proceeds of the offering of the units will be approximately $6 million. Each unit will consist of one share of common stock and one Series G warrant. Each Series G warrant will entitle the holder to acquire one share of common stock at an exercise price of $1.90 per share, subject to adjustment, for a period of five years following the date of issuance.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Initiates Clinical Trial For Bordatella Direct Test
BusinessWire - Tue May 17, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it has initiated a clinical trial for its sample-to-result Bordatella Direct Test, which will detect, directly from patient specimen, Bordatella pertussis, a bacterium causing a highly contagious respiratory disease commonly known as whooping cough. This is the first of five clinical trials the Company plans to initiate in 2016.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Reports First Quarter 2016 Results
BusinessWire - Thu May 12, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostic testing company, today reported financial results for the first quarter ended March 31, 2016.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Announces Rescheduling of Nasdaq Hearing
BusinessWire - Tue May 10, 3:45PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, today announced that it has received notice from Nasdaq that the date of its hearing before the Nasdaq Listing Qualifications Panel (the "Panel"
has been rescheduled by Nasdaq from mid-May to mid-June, and therefore the Company now expects a decision from the Panel in mid-July. GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Great Basin Expands Product Development Leadership
BusinessWire - Wed Apr 27, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, has appointed Suzette Chance, Ph.D. to serve as senior director of clinical affairs. In her role, Dr. Chance will lead clinical trial strategy and execution for Great Basin's diagnostic products, beginning with upcoming trials for: Candida Blood Infections Panel; SA Nasal Screen Test; CT/NG Test; Stool Bacterial Pathogens Panel; and Pertussis/Parapertussis Test. All five trials are slated to begin in 2016 with expected clearance timeframes throughout 2017.
GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28)
Emerging Growth Mobile App Friendable, FDBL The Next Big Thing - Stocks To Watch For This Summer
ACCESSWIRE - Mon Apr 18, 7:30AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Mobile App Friendable, (OTC Pink: FDBL) The Next Big Thing. Friendable announced surpassing 700,000 registered users and a 170% increase in registered users over January and February.
NETE: 1.27 (unch), VRX: 27.10 (-0.18), GBSN: 3.73 (-0.22), SUNE: 0.34 (unch), NXTD: 3.62 (-0.09), AAPL: 113.58 (-1.34)
4 Stocks That Are Bouncing Off 52 Week Lows For Big Gains This Morning
ACCESSWIRE - Fri Apr 15, 9:16AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. GBSN, EBIO, ORPN and EXXI are on high volume alert. Continue reading to find out why GBSN could be the most talked about stock today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EXXI: 0.13 (-0.01), GBSN: 3.73 (-0.22), GBSNU: 16.22 (-0.28), EBIO: 3.25 (-0.45), ORPN: 1.70 (-0.01)
(0)
(0)Scroll down for more posts ▼